<DOC>
	<DOCNO>NCT01349972</DOCNO>
	<brief_summary>This randomized phase II trial study alvocidib , cytarabine , mitoxantrone hydrochloride work compare cytarabine daunorubicin hydrochloride treat patient newly diagnose acute myeloid leukemia . Alvocidib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cytarabine , mitoxantrone hydrochloride , daunorubicin hydrochloride work different way stop growth cancer cell , either kill cell stop dividing . It yet know whether give alvocidib , cytarabine , mitoxantrone hydrochloride effective give cytarabine daunorubicin hydrochloride treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Alvocidib , Cytarabine , Mitoxantrone Hydrochloride Cytarabine Daunorubicin Hydrochloride Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare rate complete remission ( CR ) 1 course induction therapy timed-sequential combination alvocidib ( flavopiridol ) , cytarabine ( cytosine arabinoside [ ara-C ] ) , mitoxantrone hydrochloride ( FLAM ) vs traditional `` 7+3 '' cytarabine daunorubicin hydrochloride ( ara-C + Daunorubicin ) adult ( age 18 70 ) newly diagnose , previously untreated , intermediate-risk poor-risk acute myelogenous leukemia ( AML ) . SECONDARY OBJECTIVES : I . To evaluate compare toxicity FLAM vs 7+3 . II . To compare 2-year disease-free survival ( DFS ) overall survival ( OS ) response FLAM v 7+3 . III . To detect compare presence minimal-residual disease ( MRD ) remain FLAM v 7+3 . IV . To determine expression ABC transport protein multidrug resistance 1 ( MDR1 , ABCB1 ) breast cancer resistance protein ( BCRP , ABCG2 ) AML blast pretreatment correlate expression one proteins CR DFS response FLAM v 7+3 . OUTLINE : This multicenter study . Patients stratify accord risk feature : age ( &lt; 50 v &gt; = 50 ) , secondary AML ( pre-existing myelodysplatic syndrome [ MDS ] , myeloproliferative disease [ MPD ] , treatment-related [ ] -AML , severe multi-lineage dysplasia ) and/or know adverse cytogenetics , hyperleukocytosis ( white blood cell [ WBC ] &gt; = 50,000/mm^3 ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive alvocidib intravenously ( IV ) 1 hour day 1-3 , cytarabine IV 72 hour day 6-8 , mitoxantrone hydrochloride IV 1-2 hour day 9 . Patients achieve complete partial response first course ( completion dos ) may receive second course treatment high-dose cytarabine 21-63 day follow blood count recovery , and/or undergo allogeneic bone marrow transplant . ARM II : Patients receive cytarabine IV continuously day 1-7 daunorubicin hydrochloride IV day 1-3 . Patients residual disease day 14 may receive additional cytarabine 5 day daunorubicin hydrochloride 2 day . Patients may undergo blood bone marrow collection correlative study . After completion study therapy , patient follow every 3 month 2 year , every 6 month 5 year , annually thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>All adult establish , pathologically confirm diagnose newly diagnose AML adult newly diagnose AML , exclude newly diagnose corebinding factor ( CBF ) AMLs acute progranulocytic leukemia ( APL , M3 ) , consider eligible study Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 03 Patients &gt; = 65 year age must ECOG PS = &lt; 2 prior develop leukemic symptom Serum creatinine ≤ 2.0 mg/dL Alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) = &lt; 5 time upper limit normal ( ULN ) ( unless leukemic infiltration ) Total bilirubin = &lt; 2.0 mg/dL ( unless Gilbert disease , hemolysis , leukemia ) Left ventricular ejection fraction ≥ 45 % Newly diagnose AML , subtypes M0 , 1 , 2 , 47 exclude M3 ( APL ) , include follow poor risk feature : Antecedent hematologic disorder include myelodysplasia ( MDS ) relate AML ( MDS/AML ) prior myeloproliferative disorder ( MPD ) Treatmentrelated myeloid neoplasm ( tAML/tMDS ) Myeloid sarcoma , myeloid proliferation relate Down Syndrome , blastic plasmacytoid dendritic cell neoplasm AML multilineage dysplasia ( AMLMLD ) Adverse cytogenetics ( defined 5/5q ; 7/7q ; abnormal 3q , 9q , 11q , 20q , 21q , 17p ; ( 6 ; 9 ) ; ( 9 ; 22 ) ; trisomy 8 ; trisomy 13 ; trisomy 21 ; complex karyotype ( ≥ 3 unrelated abnormality ) Patients receive hydroxyurea alone receive noncytotoxic therapy previously myelodysplasia ( MDS ) myeloproliferative disorder ( MPD ) ( e.g. , thalidomide lenalidomide , interferon , cytokine , 5azacytidine decitabine , histone deacetylase inhibitor , lowdose cyclophosphamide [ cytoxan ] , tyrosine kinase [ TK ] dual TK/src inhibitor ) eligible trial At least 24 hour since prior leukopheresis hydroxyurea cytoreduction Any previous treatment flavopiridol Concomitant chemotherapy , radiation therapy , immunotherapy Hyperleukocytosis &gt; = 50,000 blasts/uL ; leukopheresis hydroxyurea may use immediately prior study drug administration cytoreduction ; must stop 24 hour first dose study chemotherapy CBF AMLs associate ( 8 ; 21 ) M4eo subtype ( inv [ 16 ] [ 16 ; 16 ] ) , diagnose morphologic criterion , flow cytometric characteristic , rapid cytogenetics FISH molecular test Acute Progranulocytic Leukemia ( APL , M3 ) Active central nervous system ( CNS ) leukemia Active , uncontrolled infection ; patient infection active treatment control antibiotic eligible Active , uncontrolled graft vs. host disease ( GVHD ) follow allogeneic transplant nonAML condition ( e.g . MDS , lymphoid malignancy , aplastic anemia ) ; patient GVHD control stable dos immunosuppressant eligible Presence lifethreatening illness Patients mental deficit and/or psychiatric history preclude form give informed consent follow protocol Pregnant nursing patient exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>